Caryota Labs India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 18-07-2024
- Paid Up Capital ₹ 0.63 M
as on 18-07-2024
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 18.12%
(FY 2022)
- Profit 31.97%
(FY 2022)
- Ebitda 41.44%
(FY 2022)
- Net Worth -17.83%
(FY 2022)
- Total Assets -10.43%
(FY 2022)
About Caryota Labs India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.63 M, as per Ministry of Corporate Affairs (MCA) records.
Ballam Reddy, Jayalakshmi, Mahadevapura Roopa, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232KA2014PTC077384
- Company No.
077384
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Nov 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Yelahanka Hobli Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Caryota Labs India?
Board Members(4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ballam Reddy | Director | Current | |
Jayalakshmi | Director | 21-Nov-2014 | Current |
Mahadevapura Roopa | Director | 21-Nov-2014 | Current |
Kainthaje Satish | Director | 11-Aug-2021 | Current |
Financial Performance and Corporate Structure Insights of Caryota Labs India.
Caryota Labs India Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 18.12% increase. The company also saw a substantial improvement in profitability, with a 31.97% increase in profit. The company's net worth observed a substantial decline by a decrease of 17.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Caryota Labs India?
In 2022, Caryota Labs India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Caryota Lifesciences India Private Limited
Active 13 years 4 monthsBallam Reddy and Kainthaje Satish are mutual person
Navadurga Health Solutions Private Limited
Active 4 years 5 monthsKainthaje Satish is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Caryota Labs India?
Caryota Labs India has a workforce of 9 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Caryota Labs India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Caryota Labs India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.